INDV - Ticker AI Digest

Indivior PLC 📰 1
TradingFloor AI GO VIP Login

Digested News

Today's Catalysts (INDV) 1
INDV 07:25
Indivior PLC
Total Voting Rights
AI 0
No items for this category on selected date.
Acquisitions 0
No items for this category on selected date.
Agreement 0
No items for this category on selected date.
Approvals 0
No items for this category on selected date.
Authorisation 0
No items for this category on selected date.
Awards 0
No items for this category on selected date.
BTC 0
No items for this category on selected date.
Blockchain 0
No items for this category on selected date.
Breakthrough 0
No items for this category on selected date.
BuyBack 0
No items for this category on selected date.
Cancellations 0
No items for this category on selected date.
CashOffer 0
No items for this category on selected date.
Collaborate 0
No items for this category on selected date.
ContractWin 0
No items for this category on selected date.
Covid-19 0
No items for this category on selected date.
Deals 0
No items for this category on selected date.
Diamond 0
No items for this category on selected date.
DirectorDealing 8
INDV 13:19
Indivior PLC
Director/PDMR Shareholding
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
<mark style="background-coloryellow">Purchase</mark> of Shares
INDV 13:17
Indivior PLC
Director/PDMR Shareholding
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
<mark style="background-coloryellow">Purchase</mark> of Shares
INDV 13:41
Indivior PLC
Director/PDMR Shareholding
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
<mark style="background-coloryellow">Purchase</mark> of Shares
INDV 13:37
Indivior PLC
Director/PDMR Shareholding
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
<mark style="background-coloryellow">Purchase</mark> of Shares
INDV 13:18
Indivior PLC
Director/PDMR Shareholding
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
<mark style="background-coloryellow">Purchase</mark> of Shares
INDV 13:16
Indivior PLC
Director/PDMR Shareholding
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
<mark style="background-coloryellow">Purchase</mark> of shares
INDV 14:38
Indivior PLC
Director/PDMR Shareholding
INDV 14:35
Indivior PLC
Director/PDMR Shareholding
Discovery 0
No items for this category on selected date.
Exceeded 0
No items for this category on selected date.
FCA 0
No items for this category on selected date.
FDA 0
No items for this category on selected date.
Grants 0
No items for this category on selected date.
InvestmentPlan 0
No items for this category on selected date.
JV 0
No items for this category on selected date.
Launch 0
No items for this category on selected date.
Litigation 0
No items for this category on selected date.
NewContract 0
No items for this category on selected date.
Offers 0
No items for this category on selected date.
Offtake 0
No items for this category on selected date.
Orders 0
No items for this category on selected date.
Partner 0
No items for this category on selected date.
Patents 0
No items for this category on selected date.
Placing 0
No items for this category on selected date.
Positive 0
No items for this category on selected date.
Proposals 0
No items for this category on selected date.
Reports 1
INDV 06:01
Indivior PLC
Half-year Report
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
Indivior PLC released its Q2 2024 financial report, highlighting a 24% increase in SUBLOCADE net revenue compared to Q2 2023. The company also announced a new $100 million share repurchase program and an expected settlement related to opioid litigation. The report includes details on financial performance, product highlights, guidance for FY 2024, and a primary U.S. listing update. The companys CEO, Mark Crossley, expressed confidence in the underlying fundamentals of the business and strategy, despite challenges in 2024. The report also covers principal risks, exchange rates, and a webcast presentation. The financial statements provide insights into the companys income, balance sheet, cash flow, and changes in equity. The notes offer additional context on the basis of preparation, accounting policies, segment information, operating expenses, taxation, and exceptional items.
Results 1
INDV 06:01
Indivior PLC
Notice of Results
Significant 0
No items for this category on selected date.
Speculation 0
No items for this category on selected date.
Strategic 0
No items for this category on selected date.
Suspension 0
No items for this category on selected date.
TR1 5
INDV 15:27
Indivior PLC
Holding(s) in Company
INDV 06:01
Indivior PLC
Holding(s) in Company
INDV 06:01
Indivior PLC
Holding(s) in Company
INDV 14:40
Indivior PLC
Holding(s) in Company
INDV 12:57
Indivior PLC
Holding(s) in Company
Takeover 0
No items for this category on selected date.
Understanding 0
No items for this category on selected date.
Updates 1
INDV 06:01
Indivior PLC
Indivior Provides Business Update
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
Indivior PLC released a business update for investors, highlighting several key areas. Firstly, the company adjusted its financial expectations for the second quarter and full year 2024, citing adverse market conditions affecting the growth of its medication SUBLOCADE. Despite this, the company maintains its medium-term financial outlook, anticipating double-digit net revenue growth and operating margin expansion. Secondly, Indivior announced the discontinuation of sales and marketing for PERSERIS due to expected financial viability issues arising from increased payor management in the category. This decision is expected to result in a reduction of approximately 130 employees and incur total charges of $65 million. Thirdly, the company provided preliminary net revenue expectations for the second quarter, with SUBLOCADE net revenue falling below expectations due to continued Medicaid disenrollments and lower-than-anticipated stocking levels. Fourthly, Indivior updated its full-year 2024 guidance, reflecting the cessation of PERSERIS sales and marketing, and reaffirmed its long-term net revenue targets. Finally, the company disclosed a settlement agreement with end payor plaintiffs in the Health Care Services Corp (HCSC) consolidated cases for $85 million, resolving the litigation.
Vaccine 0
No items for this category on selected date.
Wins 0
No items for this category on selected date.
Worth 0
No items for this category on selected date.
All Market News (Last 30 Days) 23
INDV 07:25
Indivior PLC
Total Voting Rights
INDV 13:32
Indivior PLC
Block Listings of Shares
INDV 13:19
Indivior PLC
Director/PDMR Shareholding
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
<mark style="background-coloryellow">Purchase</mark> of Shares
INDV 13:17
Indivior PLC
Director/PDMR Shareholding
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
<mark style="background-coloryellow">Purchase</mark> of Shares
INDV 06:01
Indivior PLC
Transaction in Own Shares
INDV 13:41
Indivior PLC
Director/PDMR Shareholding
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
<mark style="background-coloryellow">Purchase</mark> of Shares
INDV 13:37
Indivior PLC
Director/PDMR Shareholding
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
<mark style="background-coloryellow">Purchase</mark> of Shares
INDV 13:18
Indivior PLC
Director/PDMR Shareholding
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
<mark style="background-coloryellow">Purchase</mark> of Shares
INDV 13:16
Indivior PLC
Director/PDMR Shareholding
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
<mark style="background-coloryellow">Purchase</mark> of shares
INDV 14:38
Indivior PLC
Director/PDMR Shareholding
INDV 14:35
Indivior PLC
Director/PDMR Shareholding
INDV 06:11
Indivior PLC
Share Repurchase Program
INDV 06:01
Indivior PLC
Half-year Report
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
Indivior PLC released its Q2 2024 financial report, highlighting a 24% increase in SUBLOCADE net revenue compared to Q2 2023. The company also announced a new $100 million share repurchase program and an expected settlement related to opioid litigation. The report includes details on financial performance, product highlights, guidance for FY 2024, and a primary U.S. listing update. The companys CEO, Mark Crossley, expressed confidence in the underlying fundamentals of the business and strategy, despite challenges in 2024. The report also covers principal risks, exchange rates, and a webcast presentation. The financial statements provide insights into the companys income, balance sheet, cash flow, and changes in equity. The notes offer additional context on the basis of preparation, accounting policies, segment information, operating expenses, taxation, and exceptional items.
INDV 06:01
Indivior PLC
Transaction in Own Shares
INDV 15:27
Indivior PLC
Holding(s) in Company
INDV 06:01
Indivior PLC
Transaction in Own Shares
INDV 06:01
Indivior PLC
Notice of Results
INDV 06:01
Indivior PLC
Holding(s) in Company
INDV 06:01
Indivior PLC
Holding(s) in Company
INDV 06:01
Indivior PLC
Indivior Provides Business Update
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
Indivior PLC released a business update for investors, highlighting several key areas. Firstly, the company adjusted its financial expectations for the second quarter and full year 2024, citing adverse market conditions affecting the growth of its medication SUBLOCADE. Despite this, the company maintains its medium-term financial outlook, anticipating double-digit net revenue growth and operating margin expansion. Secondly, Indivior announced the discontinuation of sales and marketing for PERSERIS due to expected financial viability issues arising from increased payor management in the category. This decision is expected to result in a reduction of approximately 130 employees and incur total charges of $65 million. Thirdly, the company provided preliminary net revenue expectations for the second quarter, with SUBLOCADE net revenue falling below expectations due to continued Medicaid disenrollments and lower-than-anticipated stocking levels. Fourthly, Indivior updated its full-year 2024 guidance, reflecting the cessation of PERSERIS sales and marketing, and reaffirmed its long-term net revenue targets. Finally, the company disclosed a settlement agreement with end payor plaintiffs in the Health Care Services Corp (HCSC) consolidated cases for $85 million, resolving the litigation.
INDV 06:01
Indivior PLC
Transaction in Own Shares
INDV 14:40
Indivior PLC
Holding(s) in Company
INDV 12:57
Indivior PLC
Holding(s) in Company

AI Crunch

Single-Ticker AI Crunch
INDV signal theatre built from scored market catalysts, automated AI forecasts, and live trigger logic.

This is the ticker-specific AI Crunch desk for Indivior PLC. It compresses bullish and bearish catalyst scoring, best and worst AI forecast paths, and automated buy or sell trigger logic into one cockpit so users can judge conviction without hopping across screens.

Subscription Required Bullish vs Bearish Scoring AI Forecast Stack Buy / Sell Trigger Engine Catalyst Ledger
Create Account Member Login
Subscriber Unlock
Subscribe to unlock the full INDV AI Crunch cockpit.

Subscription turns this tab into a live signal desk with bullish vs bearish machine scoring, AI forecast stack comparisons, buy and sell trigger logic, and the full catalyst ledger behind every scored catalyst row.

  • AI-scored market headlines with sentiment buckets and buzzword breakdowns.
  • Forecast leaders ranked by projected gain against current market price.
  • Advanced technical scans, AI forecast stacks, and predictive MACD inside the live stock terminal charts.
  • Single-ticker AI Crunch desks with buy or sell trigger logic and full catalyst ledgers.
  • Scored earnings shock board with predicted direction, sector pulse and catalyst narrative.
  • Fast market scan built for event-driven trading, not passive dashboards.
Subscribe to unlock the ticker-specific signal stack, sentiment gauges, forecast stage, and the full catalyst ledger for INDV on 2024-08-01.

Fundamentals Matrix

Overall Fundamentals
Signal: Pending
Capital Strength
Signal: Pending
Float Liquidity
Signal: Pending
Short Pressure
Signal: Pending
Target Setup
Signal: Pending
Market Profile
Signal: Pending
Market Cap
1544652544
Enterprise Value
1735103598
Public Float
71.74
Broker Target
1049.3093
Shares Out
124770000
Long Interest
91
Short Interest
9
Exchange
LSE
Currency Code
GBX
ISIN
GB00BN4HT335
Market
LSE - MAIN MARKET
Sector
Pharmaceuticals and Biotechnology
Float / Shares Ratio
-
Short vs Long Delta
-
EV / Market Cap
-

Financials Matrix

Overall Stability
Signal: Pending
Profitability
Signal: Pending
Debt & Cash
Signal: Pending
Valuation Risk
Signal: Pending
Forward Expectation
Signal: Pending
Dividend Safety
Signal: Pending
Divi Rate
-
Ex Divi
2016-06-16
Earnings Date
2025-10-23
Net Debt
56000000.0
Cash
319000000.0
EPS
-0.04
Net Income
2000000.0
Revenue
1188000000.0
Enterprise Value
1735103598
Trailing PE
-
Forward PE
-
Price Sales TTM
1.3202
Price Book MRQ
141.0203
EV Revenue
1.7551
EV EBITDA
28.1289

Capital Radar

Capital Regime
—
Building signal blend...
Smart Money Tilt
—
Public vs institutions
Target Conviction
—
Broker coverage pulse
Insider Pressure
—
Director + TR1 flow
Last Held Position
-
Public Hands
-
Institutions
17.2006
Institutions As Of
2025-07-24
Avg Broker Target
-
Upside Vs Price
-
Purchase Director Dealing
14
Sale Director Dealing
10
Purchase TR1
16
Sale TR1
5
Broker Coverage Rows
1
Institution Holders Tracked
6
Public Vs Institutional Ownership (3D)
Top Institution Holders (Latest Per Holder)
Director Dealing Sentiment Flow
Broker Target Bias
Signal: Pending
Capital Momentum Matrix
Broker Targets Vs Price
Aggregated Institution Weight By Holder

Short Data - Last 30 Days

Nexus Pulse Engine

Overall Buy/Sell/Hold
Signal: Pending
Technical Composite
Signal: Pending
Financial Composite
Signal: Pending
Fundamental Composite
Signal: Pending
Short Pressure
Signal: Pending
Momentum Bias
Signal: Pending

Volatility Lab

ATR(14)
Realized Vol (20d)
Volume Spike Z

AI Charts

Today's Catalysts

1 live catalyst just hit INDV.

The headlines landing in Digested News are now framed here as today's catalyst tape. Scroll the tab rail to Digested News or jump there instantly below.
Live Tape Data 2024-08-01 AI Charts Landing View
Scroll the tab rail to Digested News any time, or use the jump button to land straight on today's tape.
1 Today
Catalyst Pulse
Indivior PLC has fresh news flow feeding the chart narrative.
07:25 Today's Catalyst Total Voting Rights
AI Charts Studio
INDV Price History
Live structure, automated forecasts, technical overlays and catalyst beacons in one chart workspace.
30 Day View Window 30D Data 2024-08-01 Open Preview Studio Brief
Chart Intelligence Suite
Swipe the timeframe, call the overlays, and keep the AI signal stack fused into one chart cockpit.
The mobile chart console is now framed as one connected surface so forecasting, structure, catalyst beacons and chart tools all sit inside the price workspace.

Automated signalling scans momentum shifts, crossovers and volatility breaks in real time. Automated AI forecasts map best, average and worst simulation paths forward, predictive MACD extends the momentum story, and catalyst beacons pin market-moving headlines directly onto price action so users can connect news, signals and structure without leaving the chart.

Automated Signalling Automated AI Forecasts Predictive MACD Catalyst Beacons Live Price Structure
TradingFloor AI Member Login
Indicators0
Technicals0
RSI Gauge
Price Change
AI Forecast